Toxicity and death following recreational use of 2-pyrrolidino valerophenone

Clinical Toxicology

Volumn 51, Issue 9, 2013, Pages 899-903

  Eiden, Celine ^a   Mathieu, Olivier ^a   Cathala, Philippe ^b   Debruyne, Daniele ^c   Baccino, Eric ^b   Petit, Pierre ^a   Peyriere, Helene ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c CHU CÔTE DE NACRE   (France)

Author keywords

Cathinones; Death; Designer drugs; NRG 3; PVP

Indexed keywords

2 PYRROLIDINYLVALEROPHENONE; CATHINONE; PYRROLIDINE DERIVATIVE; REAGENT; RECREATIONAL DRUG; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; DEATH; DRUG INTOXICATION; HEART ARREST; HUMAN; INTERNET; MALE; MYDRIASIS; PSYCHOSIS; RHABDOMYOLYSIS; SINUS TACHYCARDIA; SUDDEN DEATH; VISUAL HALLUCINATION;

ADULT; DESIGNER DRUGS; FATAL OUTCOME; FRANCE; HEART ARREST; HUMANS; INTERNET; MALE; NARCOTICS; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTROPIC DRUGS; PYRROLIDINES; RHABDOMYOLYSIS; TACHYCARDIA, SINUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84886609737     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2013.847187     Document Type: Article

References (21)

1. Lehner KR, Baumann MH. Psychoactive bath salts ': Compounds, mechanisms, and toxicities. Neuropsychopharmacology 2013; 38 : 243-244.
2. Ross EA, Watson M, Goldberger B. " Baths salts " intoxication. N Engl J Med 2011; 365: 967-968.
3. Fauquet JP, Morel E, Demarty C, Rapin Jr. Role of central catecholamines in the psychostimulant activity of pyrovalerone. Arch Int Pharmacodyn Ther 1976; 224: 325-337.
4. Servin A, Fauquet JP, Jacquot C, Rapin Jr. Effects of pyrovalerone on peripheral noradrenergic mechanisms. Biochem Pharmacol 1978 ; 27: 1693-1694.
5. M eltzer P C, B utler D, D eschamps J R, M adras B K. 1 - (4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: A promising class of monoamine uptake inhibitors. J Med Chem 2006; 49 : 1420-1432.
6. Benzie F, Hekman K, Cameron L, Miller C, Smolinske S. Emergency department visits after use of a drug sold as " bath salts ". Morbidity and mortality weekly report 2011; 60: 624-627.
7. Warrick BJ, Hill M, Hekman K, Christensen R, Goetz R, Casavant MJ, et al. A 9-state analysis of designer stimulant, " bath salt, " hospital visits reported to poison control centers. Ann Emerg Med 2013 ; 62: 244-251.
8. M urray B L, M urphy C M, B euhler M C. D eath following recreational use of designer drug " bath salts " containing 3,4- methylenedioxypyrovalerone. J Med Toxicol 2012; 8: 69-75.
9. EMCDDA Annual report on the state of the drugs problem in Europe. Lisbon 2012. ISBN/ISSN: 1609-6150.
10. OFDT 2012. Enqu ê te 2009 SINTES Observation sur la composition des produits de synth è se. http://www.ofdt.fr/BDD/publications/ docs/epfxemr4.pdf. Accessed September, 2013
11. ANSM 2012. ADDENDUM au compte rendu de la Commission nationale des stup é fi ants et des psychotropes du 16 juin 2011. http:// ansm.sante.fr/var/ansm-site/storage/original/application/ fb81dc38741cb1adda2423a26e0470b1. pdf. Accessed September, 2013.
12. Legifrance 2012. Arr ê t é du 27 juillet 2012 modifi ant les arr ê t é s du 22 f é vrier 1990 fi xant la liste des substances class é es comme stup é fi ants et la liste des substances 0178 du2 ao û t2012 page 12664, texte npsychotropes. Legifrance. JORF n 28. http://www.legifrance.gouv.fr/ affi chTexte. döcidTexte - JORFTEXT00002624 6525 & dateTexte -& categorieLien - id. Accessed September, 2013
13. Sauer C, Peters FT, Haas C, Meyer MR, Fritschi G, Maurer HH. New dresigner drug -pyrrolidinovalerophenone (PVP): Studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J Mass Spectrom 2009; 44: 952-964.
14. Marinetti LJ, Antonides HM. Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: Method development, drug distribution and interpretation of results. J Anal Toxicol 2013; 37: 135-146.
15. Rosenbaum CD, Carreiro SP, Babu KM. Here today, gone tomorrow. back again? A review of herbal marijuana alternatives (K2, spice), synthetic cathinones (bath salts), kratom, salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 2012; 8: 15-32.
16. Brenneisen R, Fisch HU, Koelbing U, Geisshusler S, Kalix P. Amphetamine-like effects in humans of the khat alkaloid cathinone. Br J Clin Pharma 1990; 30: 825-828.
17. Aaseb ø W. ECG-voltage in alcoholics and non-Alcoholics with acute alcohol intoxication. J Forensic Leg Med 2009; 16 : 381-384.
18. Singla S, Sachdeva R, Mehta JL. Cannabinoids and atherosclerotic coronary heart disease. Clin Cardiol 2012; 35: 329-335.
19. Ho-Sang S, Yun-Suk OS, Soha L, Byung-Bin P. Detection and identifi cation of pyrovalerone and its hydroxylated metabolite in the rat. J Anal Toxicol 1996; 20: 568-572.
20. Wood DM, Davies S, Cummins A, Button J, Holt DW, Ramsey J, Dargan PI. Energy-1 (NRG-1): Don' t believe what the newspapers say about it being legal. Emerg Med J 2011; 28: 1068-1070.
21. Brandt SD, Freeman S, Sumnall HR, Measham F, Cole J. Analysis of NRG legal highs in the UK: Identifi cation and formation of novel cathinones. Drug Test Anal 2011; 3: 569-575.